Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Corcept Therapeutics
- Study ID
- NCT03604198
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Cushing Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- relacorilant — DRUGCORT125134 is supplied as capsules for oral dosing.
Study Details
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Key Dates
- First listed
- Jul 27, 2018
- Start date
- May 7, 2018
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 125 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: relacorilant (CORT125134)
Primary Outcome Measure
Long-term safety of relacorilant [ Time Frame: 36 months ]
Locations (25)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site 49 | Phoenix | Arizona | 85013 | - |
| Site 35 | Stanford | California | 94305 | - |
| Site 39 | Torrance | California | 90502 | - |
| Site 50 | Miami | Florida | 33136 | - |
| Site 10 | Atlanta | Georgia | 30318 | - |
| Site 9 | Chicago | Illinois | 60611 | - |
| Site 1 | Indianapolis | Indiana | 46202 | - |
| Site 5 | Metairie | Louisiana | 70006 | - |
| Site 27 | Baltimore | Maryland | 21287 | - |
| Site 13 | Fall River | Massachusetts | 02721 | - |
| Site 8 | Ann Arbor | Michigan | 48109 | - |
| Site 36 | Rochester | Minnesota | 55905 | - |
| Site 34 | Jackson | Mississippi | 39202 | - |
| Site 3 | St Louis | Missouri | 63110 | - |
| Site 55 | Reno | Nevada | 89511 | - |
| Site 6 | Albany | New York | 12206 | - |
| Site 24 | New York | New York | 10021 | - |
| Site 4 | Wilmington | North Carolina | 28401 | - |
| Site 43 | Cleveland | Ohio | 44195 | - |
| Site 2 | Pittsburgh | Pennsylvania | 15212 | - |
| Site 46 | Pittsburgh | Pennsylvania | 15213 | - |
| Site 11 | Dallas | Texas | 75390 | - |
| Site 7 | El Paso | Texas | 79935 | - |
| Site 32 | Fort Worth | Texas | 76132 | - |
| Site 12 | Houston | Texas | 77079 | - |
Find similar trials in Phoenix, AZ
Related Studies
- Collecting Information About Treatment Results for Patients With Cushing's SyndromeRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromePHASE2 · Recruiting · RECORDATI GROUP · San Francisco, California
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)Recruiting · Mayo Clinic · Rochester, Minnesota
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromePHASE1/PHASE2 · Recruiting · Crinetics Pharmaceuticals Inc. · Bethesda, Maryland